Genelux Corp
General ticker "GNLX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $88.6M
Genelux Corp does not follow the US Stock Market performance with the rate: -33.1%.
Estimated limits based on current volatility of 4.0%: low 2.14$, high 2.32$
Factors to consider:
- Current price 50.6% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [4.65$, 15.98$]
- 2024-12-30 to 2025-12-30 estimated range: [3.05$, 10.40$]
Short-term GNLX quotes
Long-term GNLX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $11.07MM | $0.17MM |
| Operating Expenses | $14.61MM | $14.08MM | $24.34MM |
| Operating Income | $-14.61MM | $-3.01MM | $-24.16MM |
| Non-Operating Income | $-1.76MM | $-1.09MM | $-4.13MM |
| Interest Expense | $1.42MM | $1.41MM | $3.97MM |
| R&D Expense | $6.32MM | $9.08MM | $12.77MM |
| Income(Loss) | $-16.38MM | $-4.11MM | $-28.30MM |
| Taxes | $1.42MM | $1.10MM | $0.00MM |
| Profit(Loss) | $-17.80MM | $-5.21MM | $-28.30MM |
| Stockholders Equity | $-33.11MM | $-35.78MM | $19.47MM |
| Assets | $8.13MM | $5.53MM | $27.89MM |
| Operating Cash Flow | $-6.58MM | $-3.57MM | $-20.27MM |
| Capital expenditure | $0.00MM | $0.05MM | $1.02MM |
| Investing Cash Flow | $0.00MM | $-0.05MM | $-14.72MM |
| Financing Cash Flow | $-0.27MM | $-0.48MM | $44.02MM |
| Earnings Per Share* | $-0.75 | $-0.21 | $-1.16 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.